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Abstract
Targeting the epidermal growth factor receptor (EGFR), with inhibitors such as erlotinib, represents a promising therapeutic option in advanced Head and Neck Squamous Cell Carcinomas (HNSCC). However, they lack significant efficacy as single agents. Recently, we identified the ability of statins to induce synergistic cytotoxicity in HNSCC cells through targeting the activation and trafficking of the EGFR. However in a Phase I trial of rosuvastatin and erlotinib, statin induced muscle pathology limited the usefulness of this approach. To overcome these toxicity limitations, we sought to uncover other potential combinations employing a 1200 compound screen of approved FDA drugs. We identified monensin, a coccidial antibiotic, as synergistically enhancing the cytotoxicity of erlotinib in two cell line models of HNSCC, SCC9 and SCC25. Monensin 
Introduction
Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer and accounts for approximately 90% of the cancers occurring in the mucosa of the head and neck (1) . Presently, early stage HNSCC tumours are treated with radiation or surgery (2) and in advanced cases a multimodal approach is utilized often incorporating chemotherapy (3) . Unfortunately, long-term survival remains relatively unchanged (4) and new therapeutic options are required in order to enhance over-all survival of patients with HNSCC. Expression of the Epidermal Growth Factor Receptor (EGFR) is associated with HNSCC pathogenesis and is up regulated in 90% of these tumours (5, 6) . EGFR expression is associated with poor prognosis (7) (8) (9) . Preclinical studies that target the EGFR in HNSCC models have shown promising results (10, 11) ; however, ineffective receptor inhibition and deregulated downstream signalling pathways can lead to resistance to these agents (12) . Thus, targeting the EGFR in combination with other strategies that can overcome these resistant mechanisms is critical to enhance the efficacy of this approach.
Tyrosine Kinase Inhibitors (TKI) are a class of therapeutic agents that consist of low molecular weight ATP mimics that bind the intracellular kinase domain of receptors like the EGFR (13) . TKIs compete with and reversibly bind to the ATP binding site preventing the activation of the receptor and its downstream signal transduction cascades (13) . Gefitinib (ZD 1839, Iressa®) and Erlotinib (OSI 774, Tarceva®) are the most clinically advanced EGFR-TKIs (13, 14) . Interestingly, recent studies have revealed that a subset of NSCLC patients respond more robustly to treatment with these drugs due to the presence of mutations in the kinase domain of the EGFR (15, 16). These mutations stabilize ATP binding conferring enhanced activity to this mutated receptor, however, TKIs can also demonstrate enhanced binding to the ATP binding pocket rendering these NSCLC cells more sensitive to these agents (15, 16) .
Monensin is an antibiotic secreted by the bacteria Streptomyces cinnamonensis and classified as a polyether antibiotic or ionophore possessing a cyclic conformation with protruding alkyl groups making the molecule highly lipid-soluble (17) . This allows monensin to freely pass across the lipid bilayer of the cytoplasmic membrane or cellular organelles transporting ions along by passive diffusion (17) . During ion transport, monensin crosses the lipid membrane, loses the proton on the carboxylic group and chelates a cation then it crosses back to the opposite side of the membrane losing the ion in exchange for a proton and the cycle repeats (18) . During the past decade, monensin has been the focus of many cancer studies where its effectiveness in targeting cell lines derived from many cancer types, including renal cell carcinoma, colon cancer, myeloma, lymphoma and prostate has been demonstrated (19) (20) (21) (22) . Furthermore, Ketola et al.
compared the cytotoxic effect of monensin between malignant versus non-malignant cell lines and concluded that non-malignant cell lines are more than 20 fold more resistant than their malignant counterparts (23) . Furthermore, it has been shown to have a positive safety profile in veterinary medicine as it has been used in cattle and poultry feed for more than 40 years (17, 18) .
Our laboratory has previously identified high dose statins, a widely prescribed family of agents used to treat hypercholesterolemia (24) , as potent inducers of tumour specific apoptosis particularly in various paediatric malignancies, acute myeloid leukemias and HNSCC cells (25) (26) (27) . This led to a Phase I study in SCC evaluating lovastatin as a single agent that demonstrated potential utility likely as part of a combination based regimen (28) . We then demonstrated the potential of lovastatin to induce synergistic cytotoxicity in combination with EGFR-TKIs (29) . The mechanism of action revolves around the ability of lovastatin to target the activity of EGFR and other RTKs enhancing the cytotoxicity of EGFR-TKIs in HNSCC cells (30, 31) . These studies eventually led to a Phase I clinical trial of rosuvastatin and erlotinib at our Institute that showed disease stabilization, although the high dose of statins used had undesirable muscle pathologies in a significant number of patients (ClinicalTrials.gov Identifier: NCT00966472), suggesting an alternative approach to improve cancer targeting while minimizing the side effects of the treatment regimen. In this study, we performed a high throughput analysis of 1200 FDA approved compounds in combination with lovastatin or erlotinib and identified monensin as a potent enhancer of their cytotoxicity in two HNSCC (SCC9 and SCC25) derived cell lines. Importantly, monensin has been shown to similarly inhibit the trafficking of the EGFR as well as other receptors and may represent an alternative to statins with a similar mechanism of action.
Materials and Methods

Tissue Culture
The HNSCC SCC9 and SCC25 and the normal lung fibroblasts GM-38 cell lines were purchased from American Type Culture Collection ATCC (Rockville, MD). The SCC9 and SCC25 cells lines were authenticated employing short tandem repeat genetic profiling (Centre for Applied Genomics, Toronto, ON). PCR analysis confirmed that all cell lines showed undetectable mycoplasma contamination employing routine methodology as outlined (32) . All experiments were performed within 10 passages of 6 SCC9 and SCC25 cells and within 3 passages of the GM-38 cells. Cells were grown and maintained in Dulbecco's modified Eagle's medium (DMEM) (Cellgro, Manassas, VA, USA) supplemented with 1% (v/v) penicillin/streptomycin (Sigma Aldrich, St Louis, MO, USA) and 10% (v/v) fetal calf serum (Hyclone). Incubation settings were maintained at 37ºC and 5% CO 2 . Erlotinib (Tarceva) hydrochloride was purchased from BioVision (Mountain View, CA) and resuspended and diluted to 10mM stock in dimethyl sulfoxide (DMSO). Lovastatin was obtained from Apotex (Toronto, ON) and suspended in ethanol to 10mM. Sodium salt of monensin was purchased from Sigma-Aldrich (St Louis, MO, USA) and suspended in ethanol to 10mM solution.
High Throughput Chemical Library Screen
The SCC9 and SCC25 cell lines were treated with a chemical library of 1200 FDA-approved compounds (Prestwick Chemical, Illkirch, FRA) (33) . All compounds were supplied in a 10mM stock diluted in DMSO and were used at a final concentration of 1µM. Base-line cytotoxicity was evaluated for the drug library alone for both the 48 and 72hr time-points to be compared to the combination treatments. Two combination screen were performed (1) SCC9 and SCC25 pre-treated with 10μM lovastatin for 24hrs then exposed to the drug library at 1μM for a further 48hrs, and (2) SCC9 and SCC25 pre-treated with the drug library for 24hrs at 1μM followed by 10μM erlotinib treatment for 48hrs. The MTT assay was used to determine cell viability as described below. followed by monensin (0-5 µM) for a further 48hrs or pre-treated with monensin (0-5 µM) for 24hrs followed by erlotinib (0, 1, 5, or 10µM) for 48hrs. This sequence of treatments recapitulate the chemical library screen employed in this study. After 48 hours, 10μg/ml MTT reagent (Sigma-Aldrich) dissolved in phosphate buffered saline (PBS) was added 2 hours followed by cell lysis and MTT solubilization with 0.005N HCl (in 10% sodium dodecyl sulphate (SDS) for 24hrs. MTT activity was measured using a BioTek Synergy MX plate reader at 570nm and analyzed using Gen5 software (BioTek, Winooski, VT). The combination effects of lovastatin or erlotinib in combination with monensin were determined by the Chou-Talalay method (34) using CalcuSyn computer software (Biosoft, Cambridge, GBR). The dose-effect curves of each drug alone, and in combination, were produced by MTT assay. This data was entered into the CalcuSyn software and combination index (CI) values were graphed on fraction affected-CI (Fa-CI) plots. A CI < 1 is a synergistic interaction, CI = 1 is additive, and CI > 1 is antagonistic.
Propidium Iodide Flow Cytometry
One million SCC25 cells were seeded in 10cm plates and incubated overnight to allow for attachment and recovery. The following day, cells were pre-treated with 0, 1 or ImmunoResearch, West Grove, PA, USA). Supersignal west pico chemiluminescence substrate (Pierce) was applied to the blot and developed using Syngene bioimaging system (Syngene Bio-imaging, Frederick, MD).
Densitometric analysis was performed using the GeneTools software from Syngene (Syngene Bio-imaging). The density of the non-phosphorylated EGFR antibody was normalized with that of the actin antibody, then the density of the pY20 antibody of the 170kDa band was divided by the normalized density of the non-phosphorylated EGFR and taken as percentages. This was done in triplicate to obtain the SD of the mean.
Fluorescence Microscopy
SCC9 and SCC25 cells were seeded in 6-well plates containing a cover slip at a density of 2. The slides were then examined under a Ziess inverted microscope (Ziess, Oberkochen,
Germany) using oil immersion microscopy. A similar procedure was followed for the LDL internalization employing 1μg/mL LDL-Alexa 488 (Molecular Probes).
Transcriptome Analysis (RNAseq)
Total RNA was isolated employing the RNeasy Isolation Kit (Qiagen). mRNA expression profiling was determined using NuGen reagents (www.nugeninc.com). After amplification, libraries compatible with Illumina NGS methods were prepared using the Ovation Ultra Low Library Prep Kit (NuGen). The quality of each library was assessed using a Bioanalyzer 2100 (Agilent Technologies). Kappa Library Quant Kits (KappaBiosystems; www.kapabiosystems.com) were used for library quantitation. 
Results
Monensin Synergistically Enhances the Cytotoxicity of Lovastatin and Erlotinib
Our goal is to identify more specific agents that enhance erlotinib activity without the toxicities associated with high dose statin use in our clinical trials (28) . Thus, a high throughput drug screen to identify potential enhancers of both lovastatin and erlotinib cytotoxicity was performed. Two HNSCC cell line models, SCC9 and SCC25, were treated with a chemical library of 1200 FDA approved compounds all at a dose of 1μM, alone or in combination with either 10μM lovastatin or 10μM erlotinib and assayed for changes in cell viability employing the MTT assay. Monensin, employed as an antibiotic in animal feed (18) , enhanced the cytotoxic action of both lovastatin and erlotinib treatments in both cell lines examined (Supplemental Table 1 ). Interestingly, the EGFR TKIs gefitinib and erlotinib were also enhancers of lovastatin treatment, while the mevalonate pathway inhibitors fluvastatin and alendronate enhanced erlotinib cytotoxicity highlighting our previous identification of the synergistic cytotoxicity induced by this combination of agents (29) . As expected, MTT assay results showed increased lovastatin cytotoxicity ( Figure 1A ) and erlotinib cytotoxicity ( Figure 1B 
additive and synergistic interactions (34) . Fraction affect (on cell viability) plots were generated to show the combination effect (CI). CI values of 1 are additive, less than 1 are synergistic and more than 1 are antagonistic. In HNSCC cell lines, SCC9 and SCC25, monensin in combination with lovastatin or erlotinib resulted in a marked decrease in viability in a dose dependent manner, which was also found to be a synergistic ( Figure   1C ).
Monensin Induces a Potent Apoptotic Response in Combination with Erlotinib
To further confirm the ability of monensin to potentiate the cytotoxicity of erlotinib, we performed propidium iodide flow cytometric analysis to assess apoptosis induction (26, 29) . SCC25 and SCC9 cells were pre-treated with 1 or 5µM monensin for 24hrs, followed treatment with 10µM erlotinib alone or in combination with monensin for 24hrs; each condition performed in triplicate. The histograms of the various treatment conditions with the percentage of cells in the subG1 apoptotic peak are depicted in the upper left of each treatment for SCC25 cells (Figure 2A ). Untreated cells displayed 2.5% apoptosis; 48hrs treatment with 1µM monensin showed 4.5% while 5µM monensin for 48hrs induced a greater apoptotic response (16.4%). The erlotinib treatment response for 24hrs at a 10µM dose was similar to control (3.4%), however, pre-treatment with either 1 or 5µM monensin for 24hrs followed by 10µM erlotinib treatment for another 24hrs resulted in a marked increases in apoptotic events (14.6% and 38.7%, respectively) when compared to either monensin or erlotinib treatments alone. Additionally, combination of 5µM monensin with 10µM erlotinib showed the highest percentage of apoptosis (38.7%).
These histograms also show an increase in S phase suggesting the potential for monensin to induce an S phase cell cycle arrest as well as inducing apoptosis in SCC25 cells. The results of these flow cytometric analyses are tabulated in Figure 2B showing a statistically significant induction of apoptosis in the monensin and erlotinib combination treatments compared to either agent alone. In contrast in the normal fibroblast cell line GM-38, monensin alone or in combination with erlotinib treatment did not show significant effects on cell viability as assessed by the MTT assay ( Figure 2C , conditions identical to Figure 1C) .
Monensin Enhances the Erlotinib Inhibition of EGFR Activation
The synergistic effects of lovastatin in combination with EGFR-TKIs that we previously reported were due to its ability to inhibit EGFR activity (30) Figure 3C where pEGFR levels normalized to EGFR levels are presented that demonstrate co-operativity of monensin and erlotinib treatments with respect to EGFR inhibition. Both cell lines express wildtype EGFR at similar levels (29) .
Our previous studies demonstrated that lovastatin-induced inhibition of EGFR activity results from its ability to inhibit ligand-induced receptor trafficking and dimerization (30). Monensin is a recognized inhibitor of intracellular trafficking
including the ability to inhibit trafficking of the EGFR (37, 38) thus may share a common mechanism with lovastatin. To assess the effect of monensin on the trafficking of the EGFR in SCC25 and SCC9 cells, we utilized an Alexa-488 tagged EGF ligand and followed its trafficking using fluorescent microscopy. SCC25 and SCC9 cells were either untreated, 0.1-10µM erlotinib, 10µM lovastatin or 1µM monensin for 24hrs in serum free media and then stimulated with the 50ng/ml of tagged EGF for 15min. As shown in 
cells, we evaluated the expression of ATF3 in both SCC25 and SCC9 cells following monensin treatment. Monensin induced a potent induction of ATF3 in SCC9 but not in SCC25 under these conditions ( Figure 5B ) suggesting that monensin can induce apoptosis through different and independent mechanisms in these two cell lines.
Treatment of Ex-Vivo Tumour Tissue Samples with Monensin
To assess the potential of monensin to induce either HMG-CoA ( Figure 6A) reductase ( Figure 6A ) and/or ATF3 ( Figure 6B ) mRNA expression in a more clinically relevant model, we assessed ex-vivo HNSCC tumour tissue in culture from 4 different HNSCC patients undergoing surgery at our Institute (HN01-04), a non-cancerous hyperplastic epithelial lesion (HN05) and an oropharynx lymphoma (HN06). We also similarly evaluated 2 lung cancer (LU) and 2 ovarian (OV) cancer patient tumour tissues.
Tissue samples were processed following surgical excision into 2x1mm slices, randomized with 3 tissue slices evaluated per treatment ( Figure 6C ) and analyzed by quantitative RT-PCR performed in triplicate. In our previous studies employing lovastatin treatments, HMG-CoA reductase induction was generally to a lower extent than ATF3 (29, 35) .
In the ex-vivo tissue samples evaluated, 7 of 10 showed induction of greater than 2 fold of HMG-CoA reductase mRNA levels following 1 and 10μM monensin treatments Table 3 , Patient Characteristics).
Discussion
The use of erlotinib in treatment regimens of cancers with EGFR activating mutation such as in 10% of NSCLC patients has demonstrated a promising although modest improvement in patient outcomes (15, 16). In these patients, erlotinib shows enhanced binding affinity to the EGFR kinase domain demonstrating a more robust inhibition of this receptor (15, 16). In tumour types like HNSCC that over-express wild type EGFR to enhance pathway activation, erlotinib treatments have not demonstrated significant clinical activity (6, 10) . This is likely the result that erlotinib as a single agent may not inhibit wild type EGFR sufficiently to invoke a clinical response in these patients. Combining erlotinib with agents that can co-operate to target EGFR may enhance activity and uncover a novel therapeutic approach. To this end, our previous work has identified the mevalonate pathway as an important regulator of EGFR activity and that inhibiting the rate limiting enzyme of this pathway with statins inhibits EGFR activation and can induce synergistic cytotoxicity with erlotinib in wild type EGFR possessing HNSCC and NSCLC cells (29, 30) . In fact, a retrospective analysis of the Monensin has been previously shown to induce cytotoxicity in a variety of cancer derived cell lines including prostate, colon and leukemias (19) (20) (21) (22) . Moreover, monensin's cytotoxicity appeared to be cancer-specific as monensin differential sensitivity was observed between sensitive malignant versus resistant non-malignant prostate-derived cell lines (23) . In this study, we have shown that monensin mimics the inhibitory effects of lovastatin on EGFR activity. Monensin can inhibit cellular trafficking of both the EGFR and LDL receptor (37, 41) and in this study we confirmed this inhibition in cell lines and is a known inhibitor of trafficking on many levels due to its influence on the ER and golgi bodies, pH of endosomes, and protein glycosylation (44, 45) .
Monensin is used extensively in poultry and cattle feed as it can increase muscle mass in livestock (18) The mechanism by which monensin enhances erlotinib cytotoxicity in HNSCC cells is unknown. It may involve its ability to further inhibit EGFR in an unrelated mechanism to erlotinib enhancing EGFR inhibition and cytotoxicity as suggested in this study. Monensin may also enhance erlotinib activity through its ability to inhibit autophagy, a strategy that has demonstrated the potential to enhance erlotinib cytotoxicity in NSCLC cells (46) . Furthermore, lipoprotein lipolysis can lead to the induction of ATF3 resulting in apoptosis (47) and the potential of monensin to target lipid homeostasis suggest this as an alternative mechanism. Thus, combining monensin with erlotinib requires further study to delineate the mechanism of their synergistic cytotoxic response in HNSCC and to determine their utilization as a potential novel therapeutic strategy. 
